Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib and Envafolimab in ES-SCLC
NCT06698965Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Shanghai Chest Hospital. Started Oct 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06698965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698965.